IN RESPONSE: Ms. Lemon and colleagues accurately note that estimating the number of Americans who are or have ever been incarcerated is difficult even for the Bureau of Justice Statistics, the agency tasked with collecting data on all U.S. justice systems. In our introduction, we state that more than 20 million Americans are or have been incarcerated-a conservative estimate to provide the context of our primary finding, namely, that the National Institutes of Health has a critical opportunity to expand research investigating the relationship between criminal justice involvement and health. The assertion that between 9 and 70 million Americans have experienced incarceration supports our contention that many millions of Americans would benefit from increased research aimed at the intersection of criminal justice and health.
In April, The New York Times reported that 1.5 million black men aged 25 to 54 years are missing from urban centers nationwide right now-some because of early death, most because of incarceration-and described dire health-related implications for those left behind (1) . As we and others have shown, most national surveys do not include incarcerated persons, resulting in a misrepresentation of U.S. political, economic, social, and health conditions in general and among African Americans in particular (2) (3) (4) . Because incarcerated persons are literally not counted, they are invisible to many social institutions, lawmakers, and nearly all health sciences research (5) . As a result, the health effects of incarceration on prisoners' families and communities-and on prisoners' health after release-are understudied. Even if we knew the exact number of Americans who are or have been incarcerated, that number would still grossly underestimate the overall health effects associated with the epidemic of incarceration in the United States.
Ms. Lemon and colleagues are correct: Our nation should systematically enumerate how many Americans are or have been incarcerated as a basic matter of public and health policy. Meanwhile, criminal justice reform is gaining momentum nationwide and is increasingly bipartisan, as evidenced by this year's Bipartisan Summit on Criminal Justice Reform. Such reform would reduce mass incarceration, ensure access to community-standard health care for prisoners, provide meaningful rehabilitation, and address soaring system-wide costs. Health is at the core of each of these issues, yet voices from the health care community are largely absent from the conversation surrounding criminal justice reform in the United States. It is time for leadership from health care research to ensure that evidence-based health care solutions play a central role in ongoing criminal justice reform, and federal funding for such research is needed to make that vision a reality. We question these conclusions in light of a reanalysis of the all-cause mortality data. The authors excluded 0-totalevent trials and used an inverse variance-weighted fixedeffects model for pooling rare events. This model relies on large sample theory and has shown poor performance with rare events in simulation studies (2) . We repeated the analysis including all trials and used a Mantel-Haenszel (MH) weighted fixed-effects model and treatment-group continuity correction (most trials had no outcome events for the primary outcomes), as previously described for rosiglitazone studies (3). This analysis found that the effect estimate for all-cause mortality is, indeed, sensitive to the exclusion of 0-total-event trials (OR, 0.62 [CI, 0.37 to 1.04]).
Given the lack of a prepublicized protocol, we view abstract statements about reducing all-cause and cardiovascular mortality as overly positive and incorrect. Considering the potential effect of Navarese and colleagues' review on the ongoing decision process for a marketing authorization, highlighting this limitation of the reported analysis is imperative. Lack of a prepublicized protocol also raises concerns about the ad libitum presentation of certain secondary safety end points, given that most studies on PCSK9 inhibitors, as well as the ongoing cardiovascular outcomes trials, use a composite cardiovascular end point (including death, myocardial infarction, hospitalization for unstable angina, stroke, or coronary revascularization).
Finally, the review's clinical relevance is attenuated by the short duration of most of the included trials that were designed to assess surrogate end points. Findings are dominated by the single largest trial, which had relatively high discontinuation rates after 78 weeks of treatment (28% for alirocumab and 24% for placebo) (4).
We believe that, given the observed vibration of effects for hard cardiovascular end points and pending completion of long-term randomized, controlled trials, it remains uncertain whether PCSK9 inhibitors confer additional cardiovascular benefits beyond high-intensity statin therapy.
TO THE EDITOR:
Navarese and colleagues' meta-analysis (1) suggests that PCSK9 antibodies provide large benefits and decrease deaths in hypercholesterolemic adults. Unfortunately, the Data Synthesis and Statistical Analysis section omits details about the pooling and continuity correction method that was used (namely, the management of 0 cells when calculating the OR).
To reach the published results (OR for all-cause mortality, 0.45 [CI, 0.23 to 0.86]), the authors probably used a combination of the Woolf fixed-effect-based method and the treatment-group continuity correction suggested for 0 cells (2) , excluding the 0-total-event trials. We disagree with the inverse variance Woolf method used for pooling. The metaanalysis of the end point of death involves 23 trials and 10 159 participants, but only 19 and 21 participants in the intervention and control groups, respectively, died in a follow-up between 8 and 104 weeks (≤52 weeks in 19 of 23 trials).
Analysis of rare data poses questions about pooling methods: The Peto OR, which is gold standard for metaanalyses of rare events (3), is useless in the presence of unbalanced groups (such as those in the PCSK9 antibody analysis), and the Woolf method is severely biased in the presence of rare events (2, 3). We agree with Liakos and associates' comment criticizing the approaches taken in Navarese and colleagues' meta-analysis. Using the less-biased conventional meta-analytic approach in the presence of rare events (the MH method of pooling) and not excluding the 0-total-event trials, we independently reached the same conclusion as Liakos and associates: The results lose statistical significance (OR, 0.62 [CI, 0.37 to 1.04]). By excluding the 0-total-event trials and applying the same continuity correction but using the correct MH method of pooling, the result is significant but of smaller magnitude than that reported in the meta-analysis (OR, 0.54 [CI, 0.30 to 0.96]).
Navarese and colleagues' meta-analysis (1) mainly included short trials sponsored by product makers that were designed to assess surrogate end points. A somewhat similar meta-analysis about dipeptidyl peptidase-IV inhibitors in diabetic patients showed significant and impressive mortality reductions, whereas a subsequent larger meta-analysis (4) with more trials designed to assess hard end points showed no effect on mortality and an increased risk for heart failure (risk ratio, 1.158 [CI, 1.011 to 1.326]).
In conclusion, more research involving patients with higher baseline risk for death in trials with well-balanced groups and adequate duration is needed before promoting this new costly drug class of uncertain long-term safety. methods and approach that Dr. Navarese and coworkers used in their meta-analysis of the effects of PCSK9 antibodies to reduce cardiovascular and all-cause mortality among adults with hypercholesterolemia. The authors did, indeed, use the fixedeffects MH method with inverse variance weighting to summarize the data. The treatment-group continuity correction recommended by Sweeting and colleagues (1) was used to compensate for 0 events in the PCSK9 antibody or control group. Studies reporting 0 events in both groups were excluded from the analyses.
Alessandro Battaggia, MD
Dr. Battaggia and associates' reanalysis using a fixedeffects MH method with the treatment-group continuity correction provides a more conservative estimate for the mortality outcomes (OR, 0.54 [CI, 0.30 to 0.96]). This is arguably a better approach to use when pooling rare events. We could also contend that the exact MH method, without treatmentgroup continuity correction, is a more robust estimator for ORs (CIs) when pooling these events. The exact OR (CI) for all-cause mortality using the MH method is 0.49 (0.26 to 0.91).
Either method provides more conservative estimates with larger CIs for the effects of PCSK9 antibodies on all-cause mortality, but the results obtained using either method do not alter the overall conclusion that PCSK9 antibodies may statistically significantly reduce all-cause mortality among adults with hypercholesterolemia.
The issue at stake for Dr. Liakos and colleagues is what to do with the 0-event studies. They argue that excluding these trials from the analysis overestimates the beneficial effect of PCSK9 antibodies on mortality outcomes. The practice of excluding trials with 0 events for clinical outcomes is common in systematic reviews. Trials with no events in either group do not provide sufficient information to judge the relative efficacy of an intervention. The intervention and control groups share a common exposure-hyperlipidemia, in this case. Thus, both are equally at risk for the event of interest at the start of the trial. The intervention is designed to reduce lipid levels, ultimately reducing morbidity and mortality events associated with elevated lipid levels. Studies with 0 events in both groups preclude the opportunity to judge the relative efficacy of the intervention. Such 0-event trials are said to be noninformative and should be excluded from the analysis. This is a longstanding position among methodologists and is included in the Cochrane methods guides and handbook (2) .
The actual magnitude of the effect that PCSK9 antibodies have on cardiovascular and all-cause mortality remains an open question. Dr. Navarese and coworkers' review and the accompanying editorial (3) point out that none of the trials included in the meta-analysis was of sufficient size and duration to allow us to draw definitive conclusions about the effects that these antibodies have on such clinical outcomes. Caution is always needed when interpreting summary estimates based on small studies reporting rare clinical outcomes. The definitive effects of PCSK9 antibodies on cardiovascular morbidity and mortality can be addressed only in large clinical trials of sufficient duration that are specifically designed and powered to assess these outcomes. We clearly need to await the results of 4 large clinical trials that are currently under way before we know with certainty what effect PCSK9 antibodies have on cardiovascular morbidity and mortality. men and pelvis and testicular ultrasonography were normal. Echocardiography showed a normal ejection fraction and no evidence of tamponade physiology. Primary mediastinal seminoma was diagnosed.
John E. Cornell, PhD
We initiated emergent etoposide and cisplatin therapy. During the first cycle, the patient had an increasing oxygen requirement; oxygen saturation was 90% on room air and did not increase with supplemental oxygen. Arterial blood gas was analyzed while the patient was on a nonrebreather face mask and showed a pH of 7.49, PO 2 of 28 mm Hg, and PCO 2 of 78 mm Hg (alveolar-arterial gradient of 600 mm Hg). Results of computed tomography using a pulmonary embolism protocol were negative for pulmonary embolus, infection, and pulmonary edema. A second echocardiography was done, this time with agitated saline, and showed a moderate-tolarge RTLS through a patent foramen ovale (PFO) (Supplement, available at www.annals.org).
The large alveolar-arterial gradient was most likely due to a preexisting small PFO that was stretched because of external compression by the large mediastinal tumor. We prescribed aspirin and low-molecular-weight heparin therapy because of the risk for stroke from the RTLS. Closure of the PFO was considered but deferred.
The patient received 4 cycles of etoposide and cisplatin. After 2 months of chemotherapy, the shunt physiology resolved and he no longer required supplemental oxygen. Four months after diagnosis, the patient had returned to an active lifestyle and had no hypoxia. Follow-up imaging showed nearcomplete resolution of the mass (Figure, panel D) .
Discussion: Generally, RTLS across an interatrial septal defect is not considered a plausible cause of hypoxemia in the absence of elevated right-sided pressures. Godart and colleagues (1) challenged this theory in a report of 11 cases of RTLS causing hypoxemia without elevated pressures. They postulated 2 explanations. First, a local interatrial pressure gradient may occur in patients with right atrial myxomas and right ventricular infarction and during mechanical ventilation despite normal right-sided pressures (2, 3) . A second theory, known as the "flow phenomenon," proposes that blood returning to the right atrium through the superior vena cava, or, more commonly, the inferior vena cava, is preferentially directed at the fossa ovalis (4). This phenomenon has been reported in patients with persistent eustachian valve and intraoperatively (5). The second theory, combined with stretching of the PFO, is most applicable to our patient.
Displacement of atrial orientation toward the horizontal axis places the atrial septal defect in line with blood flow from the inferior vena cava. In our patient, this "streaming" across the PFO, due to the superior vena cava obstruction and the mechanical pull of the mass on the vasculature itself, provided a plausible mechanism for the RTLS.
This case has important management implications. First, it is reasonable to apply watchful waiting rather than emergent closure of a PFO when there are treatable causes for the RTLS. Second, because risk for paradoxical embolism through the stretched PFO is increased with RTLS, systemic anticoagulation should be considered. 
Michael

